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Th17 cells are potent mediators in autoimmune
diseases, and RORgt is required for their develop-
ment. Recent studies have shown that RORgt+
Treg cells in the gut regulate intestinal inflammation
by inhibiting effector T cell function. In the current
study, we report that RORgt+ Treg cells were also
found in lymph nodes following immunization. Not
only distinct from intestinal RORgt+ Treg cells in
their transcriptomes, peripheral RORgt+ Treg cells
were derived from Foxp3+ thymic Treg cells in an
antigen-specific manner. Development of these
RORgt+ Treg cells, coined T regulatory 17 (Tr17)
cells, depended on IL-6/Stat3 signaling. Tr17 cells
showed suppressive activity against antigen-spe-
cific effector T cells in vitro. In addition, Tr17 cells
efficiently inhibited myelin-specific Th17-cell-medi-
ated CNS auto-inflammation in a passive EAE
model. Collectively, our study demonstrates that
Tr17 cells are effector Treg cells that potentially
restrict autoimmunity.
INTRODUCTION
Interleukin-17 (IL-17)-producing T helper cells (Th17 cells) have
been associated with the progression of autoimmune diseases
(Dong, 2008). An orphan nuclear hormone receptor, RORgt, is
required for the development of Th17 cells; RORgt-deficient
T cells are impaired in Th17 differentiation (Ivanov et al., 2006).
Accordingly, in an experimental autoimmune encephalomyelitis
(EAE) model, the severity of autoimmunity in the CNS is signifi-
cantly decreased in RORgt-deficient mice compared with con-
trol mice, along with the decreased Th17 cells in the CNS, indi-Ce
This is an open access article under the CC BY-Ncating that RORgt-dependent Th17 generation is critical for the
development of CNS autoimmunity (Ivanov et al., 2006).
Foxp3+ regulatory T cells (Treg cells) are essential for prevent-
ing autoimmunity against self-antigens and preventing tissue
destruction resulting from excessive immune responses. Recent
studies have shown that Treg cells differentiate into distinct sub-
sets to inhibit distinct T helper cell subsets (Campbell and Koch,
2011; Sakaguchi et al., 2013). For example, T-bet+CXCR3+ Treg
cells are required for the inhibition of Th1 cell-mediated inflam-
mation, whereas Irf4 expression in Foxp3+ Treg cells is neces-
sary to prevent Th2 cell-mediated spontaneous immunopa-
thology (Koch et al., 2009; Zheng et al., 2009). In addition,
CXCR5+ follicular regulatory T cells (Tfr cells), whose develop-
ment is dependent on Bcl6, are critical for regulating germinal
center reactions mediated by CXCR5+Bcl6+ follicular helper
T cells (Tfh cells) (Chung et al., 2011; Linterman et al., 2011).
Moreover, selective Stat3 or IL-10R deficiency in Treg cells led
to dysregulation of Th17 cell responses and subsequent devel-
opment of inflammation in Th17-cell-rich mucosal tissues such
as the lung, skin, and intestine, suggesting that IL-10-mediated
Stat3 activation in Treg cells is critical for Th17 regulation
(Chaudhry et al., 2009, 2011).
RORgt+Foxp3+CD4+ T cells or IL-17-producing Foxp3+ Treg
cells have been demonstrated both in mice and humans (Du
et al., 2014). However, whether RORgt+Foxp3+CD4+ T cells
represent a subset of Treg cells, a precursor of Th17 cells, or
an intermediate differentiation stage with a bipolar potential
to develop into either Treg cells or Th17 cells has been a
matter of debate. Human studies showed that CD4+CD25hi
CD45RAHLA-DR Treg cells or CD4+CD25hiCCR6+ Treg cells
produce IL-17, but their suppressive activity against effector
cells is maintained unless the stimulation is too strong (Beriou
et al., 2009; Voo et al., 2009). A mouse study also found that
RORgt+Foxp3int cells that highly express membrane-bound
transforming growth factor b (TGF-b) can regulate autoimmune
diabetes (Tartar et al., 2010). In contrast, several mouse studiesll Reports 21, 195–207, October 3, 2017 ª 2017 The Author(s). 195
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Induction of RORgt+CCR6+ Treg Cells after Immunization
C57BL/6 mice were s.c. immunized with MOG/CFA. Seven days later, dLNs were isolated for analysis.
(A and B) RORgt and CCR6 expression in CD4+Foxp3+ cells or CD4+Foxp3 cells was analyzed by flow cytometry (A) and shown as graph (B). Non-immunized
mice were included as a control.
(C) Expression of CCR6, CXCR3, or CXCR5 was compared with RORgt expression in CD4+Foxp3+ cells.
(D) Expression of ST2 or Bcl6 was compared with RORgt expression in CD4+Foxp3+ cells.
Data are representatives of at least two independent experiments. **p < 0.005.identified RORgt+Foxp3+ cells as one of the intermediate stages
during Th17 cell development both in vitro and in vivo, although
their function has not been addressed (Ichiyama et al., 2008;
Yang et al., 2008; Zhou et al., 2008). In addition, others found
that RORgt expression in Foxp3+ cells represents an unstable
subpopulation of Treg cells that can convert to IL-17-producing
cells or pathogenic Treg cells to promote the development of
autoimmune diseases or cancer (Blatner et al., 2012; Komatsu
et al., 2014). Two recent reports demonstrated the enrichment
of RORgt-expressing Foxp3+ Treg cells in the mouse colon
(Ohnmacht et al., 2015; Sefik et al., 2015). These gut RORgt+
Treg cells originated from naive CD4+ T cell precursors, depen-
dent on intestinal microbiota. Although gut RORgt+ Treg cells are
required to inhibit intestinal inflammation mediated by Th1/Th17
cells (Sefik et al., 2015) or Th2 cells (Ohnmacht et al., 2015),
whether RORgt+ Treg cells are also present outside of the gut
and regulate peripheral T helper cell immune responses is
unknown.
In this study, we identified RORgt-expressing Foxp3+ Treg
cells that were induced in lymphoid tissues after immunization.
These RORgt+ Treg cells selectively co-expressed the chemo-
kine receptor CCR6 and represented activated Treg cells with
high proliferative potential. We found that RORgt+CCR6+ Treg
cells shared similar molecular regulation with Th17 cells for their
development, and most of them were derived from thymic Treg196 Cell Reports 21, 195–207, October 3, 2017cells. Moreover, RORgt+CCR6+ Treg cells potently inhibited
Th17-cell-mediated CNS auto-inflammation in a Th17 transfer
passive EAE model. Thus, immunization-induced lymph node
(LN) RORgt+ Treg cells, which we named T regulatory 17 cells
(Tr17 cells), represent a type of antigen (Ag)-specific effector
Treg cells with inhibitory function against autoreactive effector
T cells.
RESULTS
RORgt+CCR6+Foxp3+ T Cells Are a Distinct Treg Cell
Subset
Although RORgt+Foxp3+ Treg cells have been shown in the gut
constitutively, less than 2% of Treg cells in the peripheral lymph
nodes were RORgt+ in unimmunized C57BL/6 mice; upon sub-
cutaneous (s.c.) immunization with myelin oligodendrocyte
glycoprotein (MOG) peptide emulsified in complete Freund’s
adjuvant (CFA), about 10% of CD4+Foxp3+ Treg cells expressed
RORgt in draining lymph nodes (dLNs) (Figures 1A and 1B).
RORgt expression was highly correlated with cell surface
expression of CCR6, a chemokine receptor preferentially ex-
pressed by Th17 cells (Yamazaki et al., 2008), in both Treg
cells and non-Treg cells (Figure 1A). In addition, most of the
RORgt+ Treg cells were negative for CXCR3 and CXCR5,
markers for T-bet+ and Bcl6+ Treg cells, respectively (Figure 1C).
Figure 2. Treg Cell-Specific Cell Surface Marker Expression in RORgt+CCR6+ Treg Cells
(A) Seven days after MOG/CFA s.c. immunization, dLNs were isolated from C57BL/6 mice. Cell surface marker expression in RORgt+CCR6+CD4+Foxp3+ cells
(solid) was compared with that in RORgtCCR6CD4+Foxp3+ cells (dashed).
(B) Seven days after MOG/CFA immunization, RORgt expression in each CD4+Foxp3+ subsets in dLNs was analyzed after gating based on ICOS and CCR6
expression.
(C) Ki-67 expression in RORgt+CCR6+ (solid) or RORgtCCR6 (dashed) cells was analyzed. Data are representatives of at least two independent experiments.
See also Figure S1.Interestingly, RORgt+ Treg cells were mutually exclusive from
Bcl6+ Treg cells as well as ST2+ Treg cells, a subpopulation of
Treg cells recently identified in mucosal tissues (Figure 1D;
Arpaia et al., 2015; Molofsky et al., 2015; Schiering et al., 2014).
To characterize RORgt+ Treg cells, we analyzed the expres-
sion of Treg cell-associated cell surface molecules. Compared
with RORgtCCR6 Treg cells, RORgt+CCR6+ Treg cells highly
expressed cell activation markers, including CD25, CD44, GITR,
OX40, and CD69 (Figure 2A). In addition, the expression levels
of CD137, CTLA-4, PD-1, and BTLA, which have been attributed
to the functional aspects of Treg cells, were also higher in
RORgt+CCR6+ Treg cells than in RORgtCCR6 Treg cells. Of
note, most of the RORgt+CCR6+ Treg cells were selectively
ICOShi, resulting in exclusive expression of RORgt in ICOShi
CCR6+ Treg cells compared with ICOShiCCR6 Treg cells orICOSloCCR6 Treg cells (Figures 2A and 2B). The cell surface
marker expression pattern of RORgt+CCR6+ non-Treg cells
was very similar to that of RORgt+CCR6+ Treg cells except for
the low expression of CD137 (Figure S1). Consistent with their
activated phenotype, most of the RORgt+CCR6+ Treg cells as
well as RORgt+CCR6+ non-Treg cells were actively proliferating
cells with high levels of Ki-67 expression (Figure 2C). Collec-
tively, these results suggest that RORgt+CCR6+ Treg cells
induced following immunization are activated cells.
RORgt+CCR6+ Treg Cells Are Derived from Foxp3+
Thymic Treg Cells
Next we examined the origin and antigen specificity of RORgt+
Treg cells. To determine whether RORgt+ Treg cells are prefer-
entially derived from thymic Foxp3+ Treg (tTreg) cells or naiveCell Reports 21, 195–207, October 3, 2017 197
Figure 3. Origin of RORgt+CCR6+ Treg Cells
(A) CD4+YFP+CCR6 Treg cells isolated from Foxp3YFP-Cre reporter mice (CD45.2+) were mixed with CD4+CD25CD44loCD62L+ naive T cells isolated from
B6.SJL mice (CD45.1+) at a 1:9 ratio and then adoptively transferred to CD45.1+CD45.2+ recipient mice. One day after the transfer, recipient mice were s.c.
immunized with MOG/CFA. Seven days later, CD4+ T cells in dLNs were analyzed for Foxp3, RORgt, and CCR6 expression after gating populations based on
CD45.1 and CD45.2 expression.
(B) Helios expression in CD4+Foxp3+ or CD4+Foxp3 cells in dLNs was compared with RORgt or CCR6 expression.
(C and D) OVA-specific CD4+KJ1-26+GFP+CCR6 Treg cells isolated from DO11.10xFoxp3GFP reporter mice were adoptively transferred to BALB/c mice. One
day after the transfer, mice were s.c. immunized with OVA/CFA or KLH/CFA or left untreated. Seven days after immunization, KJ1-26+ or KJ1-26 CD4+Foxp3+
Treg cells in dLNs were analyzed for RORgt and CCR6 expression by flow cytometry (C) and shown as graph (D).
Data are representatives of two independent experiments. *p < 0.05. **p < 0.005. See also Figure S2.CD4+ T cell precursors, we co-transferred CD4+CCR6 yellow
fluorescent protein (YFP)+ Treg cells isolated from Foxp3YFP-Cre
reporter mice (CD45.2+) with naive CD4+ T cells isolated from
congenic mice (CD45.1+) into CD45.1+CD45.2+ recipient mice.
Seven days after immunization with MOG/CFA, about 10% of
host Treg cells were RORgt+CCR6+. Of interest, the majority
of the transferred CCR6 tTreg cells maintained their Foxp3
expression, and 15%–20% of them were RORgt+CCR6+ (Fig-
ure 3A). In contrast, few, if any, Foxp3+ cells were induced
from naive CD4+ T cells. These results suggest that RORgt+
Treg cells are preferentially derived from tTreg cells after immu-
nization. In support of this notion, unlike their intestinal counter-198 Cell Reports 21, 195–207, October 3, 2017parts (Ohnmacht et al., 2015; Sefik et al., 2015), more than 75%
of the RORgt+CCR6+ Treg cells induced by MOG/CFA immuni-
zation expressed Helios, one of the markers preferentially ex-
pressed by tTreg cells (Figure 3B; Thornton et al., 2010). To
directly confirm their thymic origin, we sorted Treg cells from
thymocytes of Foxp3GFP reporter mice and co-transferred
them with naive CD4+ T cells into TCRb/ mice. Seven days
after MOG/CFA immunization, we confirmed that more than
95% of the RORgt+CCR6+ Treg cells originated from thymic
Treg cells (Figure S2).
To assess whether RORgt+ Treg cell induction is antigen-spe-
cific, ovalbumin (OVA)-specific CCR6 Treg cells isolated from
DO11.10xFoxp3GFP mice were adoptively transferred to naive
BALB/c recipient mice followed by s.c. immunization with either
OVA/CFA or keyhole limpet hemocyanin (KLH)/CFA. Without
immunization, very few CD4+KJ1-26+ cells were recovered,
and less than 0.5% of KJ1-26 polyclonal Treg cells were
RORgt+CCR6+ (Figures 3C and 3D). Interestingly, however, the
numbers of OVA-specific KJ1-26+ Treg cells were remarkably
increased by OVA antigen immunization, whereas 10%–16%
of the OVA-specific Treg cells became RORgt+CCR6+. In
contrast, we could not observe any increase in the frequencies
of OVA-specific CD4+KJ1-26+ Treg cells after KLH immuniza-
tion, and most of the donor Treg cells remained RORgtCCR6.
The similar induction efficiency of RORgt+CCR6+ cells among
KJ1-26 Treg cells between OVA and KLH immunization rules
out the possibility of intrinsic differences in the immunization
protocols (Figures 3C and 3D). Altogether, these results indicate
that, unlike intestinal RORgt+ Treg cells, those in the peripheral
lymphoid tissues mainly originated from tTreg cells in an anti-
gen-specific manner after immunization.
Immunization-Induced Peripheral RORgt+Foxp3+ Cells
Are Distinct from Conventional Treg Cells or Colonic
RORgt+ Treg Cells
To further characterize RORgt+ Treg cells in their transcriptome,
we isolated RORgt+CCR6+ and RORgtCCR6 Treg cells from
dLNs of MOG/CFA-immunized Foxp3YFP-Cre reporter mice by
flow cytometry, based on their ICOS and CCR6 expression pat-
terns (Figures S3A and S3B). We confirmed that CD4+YFP+
ICOShiCCR6+ cells and CD4+YFP+ICOSloCCR6 cells represent
RORgt+ Treg cells and RORgt Treg cells, respectively, at the
mRNA level by RT-PCR (Figure S3C). Then we compared
the gene expression profiles by performing RNA sequencing
(RNA-seq) analysis. Based on transcriptomic profiling by RNA-
seq analysis, ICOShiCCR6+ Treg cells were found to be distinct
from ICOSloCCR6 Treg cells, which were relatively similar
to CCR6CXCR3CXCR5 naive Treg cells isolated from unim-
munized mice (Figures 4A–4C). A total of 3,111 genes were
differentially regulated in ICOShiCCR6+ Treg cells compared
with ICOSloCCR6 Treg cells (Figure 4D).
To sort out RORgt-dependent genes among them, we gener-
ated RORg-floxed mice and then crossed them to Foxp3YFP-Cre
mice to specifically delete RORgt in Treg cells. We then per-
formed RNA-seq analysis for CD4+YFP+ cells isolated either
from RORgf/fFoxp3YFP-Cre mice (RORgt/ Treg cells) or from
RORg+/+Foxp3YFP-Cre mice (wild-type [WT] Treg cells) 7 days af-
ter MOG/CFA immunization. When we compared differentially
regulated genes between ICOShiCCR6+ Treg and ICOSloCCR6
Treg cells with those betweenWT Treg and RORgt/ Treg cells,
102 common genes were selected (Figure 4D). Then we further
identified 29RORgt-bound loci among thembased on chromatin
immunoprecipitation (ChIP) sequencing analysis of in vitro-
generated Th17 cells (Figure 4E; Ciofani et al., 2012). Intriguingly,
a number of Th17-cell-related genes, such as Rorc, Il22, Il23r,
Il1r1, Il17a, and Il17f, were highly expressed by ICOShiCCR6+
Treg cells, suggesting that ICOShiCCR6+RORgt+ Treg cells
share some of the features of Th17 cells (Figure 4E). We
confirmed the high expression of the selected genes (Il17a,
Il17f, Il22, Il1r1, Il23r, and Il10) by ICOShiCCR6+ Treg cells atthe mRNA level, whereas the expression of irrelevant Th1-spe-
cific genes (Tbx21 and Ifng) was not increased (Figure S3C).
To see whether peripheral RORgt+ Treg cells are similar to
colonic RORgt+ Treg cells, we compared the transcriptome of
these two RORgt+ Treg populations (Sefik et al., 2015). A fold
change/fold change comparison between colonic RORgt+
Treg cells and LN RORgt+ Treg cells, after calculating the fold
change based on their respective RORgt populations, re-
vealed that several Th17-cell-related genes (Rorc, Il23r, Il1r1,
and Il17a) were highly expressed by both colonic RORgt+
Treg cells and peripheral RORgt+ Treg cells (Figure 4F). Genes
selectively upregulated in RORgt+ Treg cells in peripheral LNs
compared with colonic ones include those encoding Th17-
cell-associated effector cytokines and IL-17 receptor family
members (Il22, Il17f, and Il17re), Treg cell-associated effector
cytokines (Gzmb and Il10), a G protein-coupled receptor
(Gpr15), integrin (Itgae), chemokine receptors (Ccr2, Cxcr6,
Ccr4, and Ccr6), a costimulatory molecule (Tnfrsf8), and Helios
(Ikzf2). In contrast, the gut homing integrin and receptor (Itaga4
and Ccr9), IFN-g receptors (Ifngr1 and Ifngr2), and the transcrip-
tion factor Bcl6 were selectively downregulated in LN Treg cells
(Figure 4F). We further compared RORgt-dependent, differen-
tially regulated genes in LN Treg cells with those in colonic
Treg cells. Accordingly, several Th17-cell-associated effector
cytokines (Il17a, Il17f, and Il22) and cell surface receptors
(Il1r1 and Il17re) were selectively elevated in LN Treg cells in
an RORgt-dependent manner, whereas Il23r and the chemokine
Cxcl3 were commonly upregulated by both populations. In
contrast, expression of Th1 (Ifng) and Th2 (Il4 and Il13) effector
cytokines was significantly inhibited by RORgt in both colon and
LN Treg cells (Figure 4G). We confirmed the relatively high
expression of CCR6, CD103, Helios, and IL-17A in peripheral
RORgt+ Treg cells compared with colonic RORgt+ Treg cells
at the protein level, whereas the granzyme B expression level
was not consistent with the transcriptome analysis result (Fig-
ure 4H; Figures S3D and S3E). In contrast, the Tim-3 (encoded
by Havcr2) expression level was higher in colonic RORgt+ Treg
cells than in peripheral RORgt+ Treg cells at the protein level,
despite the common upregulation of the molecule by both pop-
ulations in a transcriptome analysis (Figures 4F and 4H). Of
note, about 10%–25% of peripheral RORgt+ Treg cells ex-
pressed IL-17A, whereas colonic RORgt+ Treg cells did not pro-
duce IL-17A (Figure 4I; Figure S3E). Based on this finding, we
named peripheral RORgt+ Treg cells Tr17 cells. Altogether,
these results indicate that immunization-induced peripheral
RORgt+ Tr17 cells are distinct from conventional Treg cells as
well as gut RORgt+ Treg cells.
Factors Involved in the Generation of RORgt+CCR6+
Tr17 Cells
Increased expression of Th17-cell-associated genes in Tr17 cells
prompted us to address whether these cells share devel-
opmental cues with Th17 cells. To test whether RORgt is
required for the generation of Tr17 cells following immuniza-
tion, RORgf/fCD4Cre mice were immunized with MOG/CFA. As
expected, the induction of RORgt+CCR6+ Tr17 cells was
completely abolished in RORgf/fCD4Cre mice (Figure 5A). Intrigu-
ingly, however, we could still detect some CCR6intICOShi TregCell Reports 21, 195–207, October 3, 2017 199
Figure 4. Transcriptional Profiling of RORgt+CCR6+ Treg Cells
(A–C) Pairwise comparison between Naı¨ve Treg versus ICOSloCCR6 Treg (A), Naı¨ve Treg versus ICOShiCCR6+ Treg (B), and ICOSloCCR6 Treg versus
ICOShiCCR6+ Treg (C). Values indicate normalized counts.
(D) Common differentially regulated genes between ‘‘ICOShiCCR6+ Treg versus ICOSloCCR6 Treg’’ and ‘‘WT Treg (WT) versus RORgt/ Treg (knockout [KO])’’
were compared and are shown in a Venn diagram. RORgt-bound gene loci identified from ChIP-sequencing data of in vitro-generated Th17 cells were further
compared.
(E) Heatmap showing 29 common differentially regulated genes selected from (D).
(F) Relatively upregulated or downregulated genes in LN ICOShiCCR6+ Treg cells (RORgt+ Treg) over ICOSloCCR6 Treg cells (RORgt Treg) were comparedwith
those in colonic RORgt+ Treg cells over colonic RORgt Treg cells. Values indicate log2 (fold change).
(G) Comparison of RORgt-dependent genes (WT versus RORgf/fFoxp3Cre mice) between colon Nrp1 Treg cells and LN Treg cells isolated from s.c. immunized
mice. Values indicate log2 (fold change).
(H) Expression of the indicated molecules in CD4+Foxp3+ cells in dLNs or the colon were analyzed by flow cytometry 7 days after MOG/CFA s.c. immunization.
(I) Antigen-specific expression of IL-17A and RORgt in CD4+Foxp3+ cells or CD4+Foxp3 cells was analyzed 24 hr after MOG peptide restimulation. Brefeldin A
and monensin were added for the last 6 hr of culture.
Data are representatives of at least two independent experiments. See also Figure S3.cells in RORgf/fCD4Cre mice, suggesting RORgt-independent
CCR6 expression in Treg cells despite the suboptimal level of
expression (Figure 5A). A previous report has shown that Stat3
in Treg cells is essential for the regulation of Th17 cells, at least
in part, by inducing the expression of CCR6 (Chaudhry et al.,
2009). Thus, we determined whether Stat3 is required for Tr17
cell generation using Stat3f/fCD4Cre mice. After immunization
with MOG/CFA, induction of RORgt+CCR6+ Tr17 cells was
completely abrogated in the absence of Stat3 in T cells, demon-200 Cell Reports 21, 195–207, October 3, 2017strating that Stat3 is indispensable for the generation of Tr17 cells
(Figures 5B and 5C). We and others found previously that ICOS-
ICOSL (B7h) signaling is critical for Th17 cell development in vivo
(Bauquet et al., 2009; Park et al., 2005). Increased expression of
ICOS in RORgt+CCR6+ Treg cells prompted us to definewhether
ICOS-ICOSL signaling is also involved in the generation of Tr17
cells. When we immunized B7h-deficient mice with MOG/CFA,
we found a significant reduction in RORgt+CCR6+ Tr17 cell gen-
eration compared with control mice (Figures 5D and 5E). Taken
Figure 5. Requirements for the Induction of RORgt+CCR6+ Treg Cells
(A) Seven days after MOG/CFA s.c. immunization of RORgf/f CD4Cre mice and littermate control RORgf/f mice, dLNs were isolated for analysis of RORgt+CCR6+
cell induction in CD4+Foxp3+ cells or CD4+Foxp3– cells.
(B) Stat3f/f CD4Cre mice and littermate control Stat3f/f mice were immunized with MOG/CFA s.c. and analyzed by flow cytometry as in (A).
(C) The result summary of (B) is shown.
(D) B7h–/– mice and control C57BL/6 mice were immunized with MOG/CFA s.c. and analyzed by flow cytometry as in (A).
(E) The result summary of (D) is shown.
(F) CD4+CCR6GFP+ Treg cells isolated from Foxp3GFP mice were stimulated with anti-CD3 and anti-CD28 antibodies (Abs) for 4 days in the presence of IL-6
(20 ng/mL) or IL-10 (100 ng/mL). RORgt and CCR6 expression in gated CD4+Foxp3+ cells was analyzed by flow cytometry.
(G) CD4+CD25hiCCR6 Treg cells isolated fromStat3f/fCD4Cremice or littermate control micewere stimulatedwith anti-CD3 and anti-CD28Abs in the presence of
IL-6 (20 ng/mL). RORgt and CCR6 expression in gated CD4+Foxp3+ cells was analyzed.
(H) CD4+CD25hiCCR6 Treg cells isolated fromRORgf/fCD4Cre mice (RORgt/ Treg) or littermate control mice (WT Treg) were transduced with a retroviral vector
expressing RORgt (RVKM RORgt) or an empty vector (RVKM). CCR6 and GFP expression was analyzed after gating on GFP+ cells.
Data are representatives of at least two independent experiments. **p < 0.005.together, these results suggest that Tr17 cells utilize similar mo-
lecular machinery for their development as Th17 cells.
RORgt Induced by IL-6-Stat3 in Treg Cells Regulates
CCR6 Expression
It has been demonstrated that IL-10-IL-10R signaling in Treg
cells is mandatory to induce Stat3 activation and subsequent
regulation of Th17 cells by Treg cells (Chaudhry et al., 2011).
Thus, we hypothesized that IL-10-mediated activation of Stat3
induces RORgt and CCR6 expression in Treg cells. To address
this hypothesis, CCR6 Treg cells isolated from Foxp3 reporter
mice were T cell receptor (TCR)-stimulated in the presenceof IL-6 or IL-10. TCR activation alone induced few, if
any, RORgt+CCR6+Foxp3+ cells. Interestingly, exogenous IL-6
induced a considerable proportion of the RORgt+CCR6+ popula-
tion among Foxp3+ cells, whereas the effect of exogenous
IL-10 was minimal (Figure 5F). As expected, Stat3 expression
in Treg cells was essential for IL-6-mediated induction of
RORgt+CCR6+Foxp3+ cells (Figure 5G).
Next we addressed whether RORgt transduction is sufficient
to induce CCR6 expression in Treg cells. To this end, we isolated
CCR6 Treg cells from RORgf/f CD4Cre mice or littermate control
mice and then transduced them with a retroviral vector express-
ing RORgt-GFP or an empty vector expressing GFP alone.Cell Reports 21, 195–207, October 3, 2017 201
Figure 6. ICOShiCCR6+RORgt+ Treg Cells Are Ag-Specific Regulatory T Cells with Potent Suppressive Activity In Vitro
(A) ICOShiCCR6+GFPCD4+ Th17 cells were isolated 7 days after MOG/CFA s.c. immunization of CD45.2+Foxp3GFP reporter mice. In parallel, ICOShiCCR6+
GFP+CD4+ Treg cells, ICOSloCCR6GFP+CD4+ Treg cells, and ICOShiCCR6GFP+CD4+ Treg cells were isolated from MOG/CFA-immunized CD45.1+CD45.2+
Foxp3GFP reporter mice. Th17 cells were stimulated withMOGpeptide (50 mg/mL) in the presence of irradiated T cell-depleted splenocytes (TdS, CD45.1+). 3-fold
serially diluted number of each Treg cells were added to the culture to test the suppressive activity. Three days later, IL-17A, IL-17F, or IL-22 production in the
culture supernatant was analyzed by ELISA.
(B) Foxp3GFP reporter mice were s.c. immunized with MOG/CFA. Seven days later, MOG-specific cells in the indicated populations of dLNs were identified by
tetramer staining.
(C) ICOShiGFPCD4+CD45.1+ T effector cells (Teffs) were labeled with CFSE (2.0 mM) and then stimulated with splenic CD11c+ dendritic cells (DCs) in the
presence or absence of ICOShiCCR6+GFP+CD4+CD45.2+ Tr17 cells in the indicated Tr17-to-Teff cell ratio. Three days later, forward scatter (FSC) value, CFSE
dilution, CD25 expression, and cytokine production of CD45.1+ Teff cells were analyzed by flow cytometry after phorbol-12-myristate-13-acetate (PMA)/
ionomycin restimulation.
Data are representatives of at least two independent experiments. *p < 0.05. **p < 0.005. See also Figure S4.AlthoughWT Treg cells expressed amarginal level of CCR6 even
without RORgt transduction, RORgt/ Treg cells were totally
deficient in CCR6 expression without RORgt transduction.
In addition, CCR6 expression was dramatically increased in
GFP+ cells of WT Treg cells by RORgt transduction in a GFP in-
tensity-dependent manner. Of note, RORgt transduction was
adequate to restore CCR6 expression in RORgt/ Treg cells
at a level comparable with that in WT Treg cells (Figure 5H).
These results suggest that RORgt expression in Treg cells is
dependent on IL-6-mediated Stat3 signaling and, in turn, that
RORgt expression is essential and sufficient for CCR6 expres-
sion in Treg cells.
RORgt+CCR6+ Tr17 Cells Have an Inhibitory Function
against Ag-Specific Th17 and Th1 Cells In Vitro
To address whether Tr17 cells can regulate Ag-specific Th17 cell
responses, CD4+ICOShiCCR6+GFP Th17 cells were isolated202 Cell Reports 21, 195–207, October 3, 2017from dLNs of MOG/CFA-immunized Foxp3GFP reporter mice.
Three days after MOG peptide stimulation, copious amounts
of IL-17A, IL-17F, and IL-22 were detected in the culture super-
natant. Of note, ICOShiCCR6+RORgt+ Tr17 cells significantly
suppressed cytokine production by Th17 cells in a Treg cell-to-
Th17 cell ratio-dependent fashion. In contrast, ICOSloCCR6
resting Treg cells failed to do so, even at the highest Treg-to-
Th17 ratio (1:1) (Figure 6A). Of interest, ICOShiCCR6+ Tr17 cells
were almost three times more potent at suppressing Ag-specific
Th17 cells than ICOShiCCR6 activated Treg cells (Figure 6A).
We also observed that ICOShiCCR6+ Treg cells were superior
at suppressing IFN-g production as well as IL-17A production by
total ICOShi effector CD4+ T cells compared with ICOShiCCR6
Treg cells and ICOSloCCR6 Treg cells (Figure S4A). These
results indicate that Tr17 cells are Ag-specific Treg cells with
potent regulatory activity against Ag-specific Th17 cells and
Th1 cells in vitro.
RORgt+CCR6+ Tr17 Cells Inhibit Proliferation and
Activation of Effector Cells
Because RORgt+ Tr17 cells exerted a more potent suppressive
function than resting Treg cells, we hypothesized that Ag-spe-
cific Treg cells were enriched within the RORgt+ subpopulation.
To test this hypothesis, we benefitted from the MOG38–49-I-A
b
tetramer, which enabled us to detect MOG-reactive CD4+
T cells by flow cytometry. Of interest, we observed that
ICOShiCCR6+ Tr17 cells contained more MOG-specific cells
than ICOShiCCR6 or ICOSloCCR6 Treg cells, suggesting
that enrichment of Ag-specific Treg cells contributed to the
enhanced suppression meditated by Tr17 cells (Figure 6B;
Figure S4B).
We then determined themode of action by which Tr17 cells in-
hibited effector T cells. After labeling CD4+GFP(Foxp3)ICOShi
effector T cells with carboxyfluorescein succinimidyl ester
(CFSE) dye to monitor cell proliferation, we restimulated the cells
with MOG peptide. Three days after restimulation, about 50% of
effector cells diluted CFSE and highly expressed the cell activa-
tion marker CD25, suggesting proliferation and activation of
MOG-specific effector T cells. When we added titrated numbers
of ICOShiCCR6+ Tr17 cells to the culture, effector cell prolifera-
tion and activation were significantly reduced in a Treg-to-T
effector cell (Teff cell) ratio-dependent manner (Figure 6C). Of
note was that the frequency of Th1 cells was considerably
reduced by Tr17 cells whereas that of Th17 cells wasmaintained
(Figure 6C). These results suggest that the suppressive mode of
action exerted by Tr17 cells might be different depending on
the type of effector T cells. We observed a similar pattern of
suppression at the single-cell level in the presence of polyclonal
restimulation (Figure S4C).
Because our transcriptome analysis revealed that Tr17 cells
upregulated the Il10 transcript, and it was confirmed by RT-
PCR (Figure 4F; Figure S3C), we tested whether IL-10 is required
for the suppression mediated by Tr17 cells. As shown in Fig-
ure S4D, Tr17 cell-mediated suppression of IL-17A and IFN-g
production by effector T cells was significantly impaired by the
anti-IL-10R blocking antibody, implying that Tr17 cell-produced
IL-10 is, at least in part, involved in their suppressive function.
RORgt+CCR6+ Tr17 Cells Can Dampen Th17-Cell-Driven
Autoimmunity
Having shown that RORgt+CCR6+ Tr17 cells are activated cells
with potent suppressive activity against Th17 cells in vitro, we
set out to assess the suppressive function of Tr17 cells under in-
flammatory conditions in vivo. To assesswhether RORgt+Foxp3+
Tr17 cells were required for the regulation of Ag-specific Th17
cells in vivo, we compared EAE progression between RORgf/f
Foxp3Cre mice and littermate control mice. Despite the potent
suppressive activity of Tr17 cells in vitro, EAE progression was
not exacerbated in Tr17 cell-deficient RORgf/fFoxp3Cre mice
compared with control mice (data not shown). We also found
that the frequency and total number of Treg cells in the CNS
were not significantly different between RORgf/fFoxp3Cre mice
and control mice, suggesting that RORgt expression in Treg cells
was not essential for CNS homing of Treg cells (data not shown).
According to a recent study, it is possible that depletion of
RORgt+ Treg cells is needed to examine their function ratherthan deletion of RORgt expression in Treg cells (Levine et al.,
2017). However, the availability of an experimental system for se-
lective depletion of RORgt+ Treg cells in vivo is limited at the
moment. To directly examine whether Tr17 cells can regulate
Ag-specific Th17 cells in vivo, we isolated CD4+YFPhi Th17
fate-mapped (Th17fm) cells from dLNs of MOG/CFA-immunized
IL-17FCrexRosa26YFP fate-mapping mice and confirmed that
about 50% of the CD4+YFPhi cells produced IL-17A after MOG
restimulation (Figure S5A). We then adoptively transferred
Th17fm cells alone or together with either ICOShiCCR6+YFP+
Tr17 cells or ICOSloCCR6YFP+ resting Treg cells (rTreg cells)
into RAG1/mice at a 4:1 Treg to Th17fm ratio (Figure S5B). Af-
ter immunization with MOG peptide emulsified in incomplete
Freund’s adjuvant (IFA) followed by pertussis toxin (PTX) injec-
tions, mice receiving Th17fm cells alone developed sequential
clinical signs of regular EAE. Notably, disease progression by
Th17fm cells was completely abrogated by co-transfer of Tr17
cells (Figure 7A). Interestingly, however, about 60% of rTreg
cell co-transfer recipient mice developed the disease with a
similar onset and severity as Th17fm cell-only transfer mice,
whereas the remainder of the mice did not develop the disease
(Figure 7A). Of note, CD4+ T cells were barely detectable in
mice receiving Tr17 co-transfer, whereas a significant infiltration
of CD4+ T cells was found in those receiving Th17fm alone or
rTreg cell co-transfer (Figures 7B and 7C). Because Th17fm cells
permanently express YFP, and its intensity is much higher than
that in Treg cells in this experimental system, we could differen-
tiate YFPhi Th17fm cells from YFPint Treg cells after induction of
EAE. Analysis of YFP expression in total CD4+ T cells in the CNS
confirmed that amajority of the CNS-infiltrated CD4+ T cells were
Th17fm cells in both Th17-only mice and diseased rTreg cell co-
transfer mice (Figure 7C). We found that most of the YFPhi
Th17fm cells had been converted to IFN-g+GM-CSF+ cells,
whereas some cells still produced IL-17A (Figure 7D). When
we analyzed YFP expression in total CD4+ T cells in the spleen,
the ratio of YFPint Treg cells to YFPhi Th17fm cells in Tr17 cell
co-transfer mice was 2.56 ± 0.72, which was about eight times
higher than that in rTreg cell co-transfer mice (0.32 ± 0.08) (Fig-
ures 7E and 7F). We also confirmed that the absolute number of
YFPhi Th17fm cells was significantly reduced by Tr17 cell co-
transfer (Figure 7G). These results suggest that Tr17 cells effi-
ciently regulated expansion of Ag-specific Th17 cells in the
periphery. Intracellular cytokine staining after MOG peptide
restimulation revealed that most of the MOG-specific Th17fm
cells in the spleen already converted to IFN-g-producing Th1
cells after EAE induction under lymphopenic conditions. The ab-
solute number and frequency of IFN-g-producing exTh17 cells
were significantly suppressed by Tr17 cells, whereas rTreg cells
marginally suppressed IFN-g production at the single-cell level
(Figures 7G and 7H). After 3 days of culture with MOG peptide,
splenocytes isolated from Th17fm-only mice produced a signif-
icant amount of IFN-g with little production of IL-17A. Interest-
ingly, IFN-g production by splenocytes was significantly reduced
by co-transfer of Tr17 cells, whereas IL-17A production was
marginally increased compared with Th17fm alone (Figures 7I
and 7J). In contrast, co-transfer of rTreg cells did not significantly
suppress IFNg production by splenocytes. Taken together,
these results indicate that thymic Treg-derived RORgt+ Tr17Cell Reports 21, 195–207, October 3, 2017 203
Figure 7. ICOShiCCR6+RORgt+ Treg Cells Can Regulate Th17-Cell-Mediated CNS Autoimmunity
CD4+YFPhi Th17 cells isolated from MOG/CFA-immunized IL-17FCrexRosa26YFP fate-mapping mice were adoptively transferred into RAG1/mice. CD4+YFP+
ICOShiCCR6+ cells (Tr17) or CD4+YFP+ICOSloCCR6 cells (rTreg) isolated from MOG/CFA-immunized Foxp3YFP-Cre mice were co-transferred with Th17 cells in
some recipient mice. All recipient mice were immunized with MOG/IFA 1 day after adoptive transfer. Pertussis toxin was injected on the day of immunization and
2 days later.
(A) The EAE score was monitored daily: Th17 alone (n = 10), Th17 + Tr17 (n = 9), and Th17 + rTreg (n = 10).
(B) The numbers of total cells and CD4+ T cells in the CNS were analyzed.
(C) Representative dot plot of YFP expression in gated CD4+CD90+ T cells in the CNS.
(D) Cytokine production in CNS CD4+YFPhi T cells was analyzed after PMA/ionomycin stimulation.
(E) YFP expression in splenic CD4+ T cells.
(F) The YFPint Treg cell-to-YFPhi Th17 fate-mapped cell ratio in the spleen was analyzed.
(G) Absolute numbers of CD4+YFPhi Th17 fate-mapped cells (Th17fm), CD4+YFPint Treg cells (Treg), and MOG-specific CD4+IFN-g+ Th1 cells in the spleen.
(H) MOG-specific cytokine production by splenic CD4+ T cells was analyzed after MOG peptide (50 mg/mL) restimulation.
(I and J) IL-17 (I) and IFN-g (J) production by splenocytes was analyzed by ELISA 3 days after restimulation with titrated doses of MOG peptide.
*p < 0.05. **p < 0.005. N.D., not detected. Data are combined results (A and F) or representatives (B–E and G–J) of two independent experiments. See also
Figure S5.cells can suppress Th17-cell-mediated CNS inflammation by re-
pressing peripheral expansion and CNS migration of Th17 cells.
DISCUSSION
Recent studies have identified intestinal RORgt+ Treg cells and
found that these microbiota-induced Treg cells are required for
the regulation of specific T helper cells in the gut (Ohnmacht204 Cell Reports 21, 195–207, October 3, 2017et al., 2015; Sefik et al., 2015). The immunization-induced
RORgt+ Tr17 cells in the current study share some features
with intestinal RORgt+ Treg cells, including a CD44hi, ICOShi,
CTLA4hi, CD103hi activated phenotype; CCR6 expression;
Stat3-dependent development; distinction from ST2+ Treg cells;
and elevated expression of genes encoding Il1r1, Il23r, Havrc2,
and Il10. However, peripheral RORgt+ Tr17 cells are distinct
from intestinal RORgt+ Treg cells. First, we found that peripheral
RORgt+ Tr17 cells are mostly Helios+Nrp-1+ tTreg cells, whereas
intestinal RORgt+ Treg cells were totally HeliosNrp-1, indi-
cating a different origin of peripherally induced Treg cells (pTreg
cells). Second, unlike intestinal RORgt+ Treg cells, about 10% of
peripheral RORgt+ Tr17 cells produced IL-17A upon restimula-
tion. Third, Stat3 was essential for the development of peripheral
RORgt+ Tr17 cells, whereas Stat3 was not absolutely required
for RORgt expression in intestinal Treg cells. Finally, gene
expression profiling data obtained from two independent tran-
scriptome analyses revealed that these two Treg cell populations
have some similarities but are distinct from each other.
The identity ofRORgt+Foxp3+ cells hasbeendebatable.Wehy-
pothesized that there are at least three different possibilities
regarding the fate of immunization-induced peripheral RORgt+
Foxp3+ cells: transient precursor cells during Th17 cell develop-
ment from naive CD4+ T cells, unstable Foxp3+ Treg cells that
can convert to IL-17-producing pathogenic cells under inflamma-
tory conditions, and an activated Treg cell subpopulation gener-
ated under a Th17-pronemicroenvironment. To address whether
a considerable proportion of Th17 cells undergo the RORgt+
Foxp3+ intermediate stage as demonstrated before (Ichiyama
et al., 2008; Yang et al., 2008; Zhou et al., 2008), we generated
Foxp3CrexRosa26YFP mice to track Th17 cells that expressed
Foxp3 at any stage throughout their developmental process.
Unexpectedly, however, we found few, if any, YFP+IL-17A+ or
YFP+IFN-g+ cells in the CNS of Foxp3CrexRosa26YFP mice after
EAE induction (data not shown). This result indicates that the
contribution of RORgt+Foxp3+ intermediate precursors to the to-
tal Th17 cell pool is minor, at least in our EAEmodel. In addition, a
low expression level of IL-17A compared with that of Th17 cells
and no evidence for pathogenic potential in our cell-adoptive
transfer EAE experiment indicate that peripheral RORgt+Foxp3+
cells are not a distinct IL-17-producing pathogenic cell popula-
tion. Finally, high expression of Treg cell-associated cell surface
molecules, stable expression of Foxp3, increased proliferative
potential, Stat3-dependentdevelopment, andstrong suppressive
activity against effector cells suggest that peripheral RORgt+
Foxp3+ cells are activated Treg cells with potent suppressive ac-
tivity induced under a Th17-prone microenvironment in a Stat3-
dependent manner, as suggested previously (Yang et al., 2015).
Although we have observed that RORgt+ Tr17 cells had strong
suppressive activity against MOG-specific Th17 cells in vitro and
in vivo, we did not see any difference in onset and severity of the
EAE between RORgt+ Treg cell-deficient RORgf/fFoxp3Cre mice
and WT mice. It is more plausible that RORgt and CCR6 expres-
sion is rather a phenotypic marker of the Ag-specific activated
Treg cells generated under the Th17-cell-promoting microenvi-
ronment than a functional component necessary for Treg cell ac-
tivity. Considering that the total ICOShi Treg cell frequency was
not changed after immunization, even in the absence of RORgt
(Figure 4A), ICOShiCCR6 Treg cells might have compensated
for the absence of ICOShiRORgt+CCR6+ Treg cells in RORgf/f
Foxp3Cre mice. A recent study demonstrated that depletion
of T-bet+ Treg cells rather than deletion of the Tbx21 gene in
Treg cells resulted in Th1-dependent immunopathology (Levine
et al., 2017). In this regard, selective depletion of RORgt+CCR6+
Treg cells after their development is required to address the
functional relevance of the population in EAE, as suggested pre-viously (Kim et al., 2007). Another possibility is that the numbers
of Tr17 cells generated in EAE were not sufficient to suppress
autoimmunity during an excessive inflammation reaction.
The role of CCR6 in EAE has been controversial (Elhofy et al.,
2009; Kleinewietfeld et al., 2005; Liston et al., 2009; Moriguchi
et al., 2013; Reboldi et al., 2009; Villares et al., 2009; Yamazaki
et al., 2008). We and others have demonstrated that CCR6
expression is required for Th17 cells to enter into the CNS to
initiate CNS inflammation by showing that EAE development is
attenuated in CCR6-deficient mice (Liston et al., 2009; Reboldi
et al., 2009; Yamazaki et al., 2008). In contrast, others showed
that CCR6 deficiency exacerbated EAE progression by regu-
lating different immune cells, such as Treg cells or dendritic cells
(Elhofy et al., 2009; Villares et al., 2009). In the current study, we
found that most of the adoptively transferred RORgt+CCR6+
Tr17 cells reside in the periphery without migrating to the CNS,
whereas they suppress MOG-specific Th17-mediated CNS
inflammation in a Th17 cell transfer EAE model (Figures 7C and
7E). In addition, Treg cell-specific deletion of RORgt in RORgf/f
Foxp3Cre mice did not critically affect the CNS homing of Treg
cells after EAE induction (data not shown). These results indicate
that RORgt-dependent CCR6 expression in Treg cells is neither
sufficient nor necessary for CNS homing of Treg cells. As previ-
ously suggested by others, it is conceivable that CCR6 expres-
sion is not required for Treg cells to migrate to the CNS when
CNS inflammation is initiated by Th17 cells (Reboldi et al.,
2009). Also, we do not rule out RORgt-independent CCR6
expression in Treg cells because we detected CCR6int Treg cells
even in the absence of RORgt. The role of CCR6 in EAE progres-
sion warrants a more detailed analysis with cell-type-specific
deletion of CCR6 in different immune cells.
The role of Treg cells in human multiple sclerosis has been
unclear. Although the frequency of CD4+CD25hi Treg cells in
peripheral blood was not significantly different between multiple
sclerosis (MS) patients and healthy subjects, a decrease in
Foxp3 expression and a defect in Treg function have been found
in MS patients (Kleinewietfeld and Hafler, 2014; Venken et al.,
2008; Viglietta et al., 2004). In contrast, a recent study did not
support that Treg function is defective in MS patients (Michel
et al., 2008). Because most of these studies focused on conven-
tional Treg cells, it is important to dissect Treg cell subsets based
on additional cellular markers. In this regard, it has been reported
that CD103+ Treg cells are increased in relapsing-remitting MS
patients, especially after IFN-b treatment (Venken et al., 2008).
In addition, CD39+ Treg cells that are selectively required for
Th17 cell regulation have been identified in MS patients (Borsel-
lino et al., 2007). Whether a human counterpart for RORgt+ Tr17
cells can be found in MS patients and whether there is any rela-
tionship between the frequency of RORgt+CCR6+ Treg cells and
the progression of MS will be important questions to be eluci-
dated in the future.
Overall,we found thatRORgt+CCR6+Foxp3+Tr17cells induced
by s.c. immunization represent activated Ag-specific effector reg-
ulatory T cells. RORgt+ Tr17 can regulate Th17-mediated CNS
autoimmunity by inhibiting the peripheral expansion and CNS
migration of myelin-specific Th17 cells. This study will provide a
guide to the development of an effective Treg cell immunotherapy
against multiple sclerosis and other autoimmune diseases.Cell Reports 21, 195–207, October 3, 2017 205
EXPERIMENTAL PROCEDURES
Mice
Mice were bred and maintained in the specific pathogen-free (SPF) animal fa-
cility at the University of Texas (UT) MD Anderson Cancer Center in accor-
dance with institutional guidelines. We generated RORgf/f mice in which exons
2 and 3 of the Rorc gene are flanked by LoxP sites. The resultant RORgf/f mice
were bred to FLPeR mice to remove the Neomycin resistance cassette and
then backcrossed to C57BL/6 mice for six generations. Foxp3YFP-Cre knockin
mice and Foxp3GFP reporter mice were kindly provided by Dr. Alexander Ru-
densky (Memorial Sloan Kettering Cancer Center). Foxp3GFP-Cre bacterial arti-
ficial chromosome (BAC) transgenic mice were kindly provided by Drs. Jeffrey
Bluestone (University of California, San Francisco [UCSF]) and Shao-Cong Sun
(UT MD Anderson Cancer Center). Stat3f/fCD4Cre and B7h/ mice were
described previously (Nurieva et al., 2003; Yang et al., 2007). C57BL/6 and
BALB/c mice were purchased from Jackson Laboratories. Foxp3GFP reporter
mice on the BALB/c background and DO11.10 mice were obtained from Jack-
son Laboratories and crossed in our animal facility. Female and male mice at
8–12 weeks of age were used for experiments.
Antigen-Specific Induction of RORgt+CCR6+ Treg Cells In Vivo
CD4+KJ1-26+CCR6GFP+ Treg cells isolated fromDO11.10xFoxp3GFP/Y male
mice were adoptively transferred into BALB/c recipient mice. One day after
the transfer, recipient mice were left untreated or immunized with either
OVA (grade V, Sigma) or KLH (Sigma), both of which were emulsified in IFA
supplemented with M. tuberculosis extract. Seven days after immunization,
CD4+KJ1-26+ T cells in draining inguinal lymph nodes were analyzed for
RORgt, CCR6, and Foxp3 expression.
Induction of EAE
For active EAE induction, mice were immunized s.c. with MOG35–55/CFA at the
tail baseonday0.Pertussis toxin (ListBiological Laboratories)was injected intra-
peritoneally (i.p.) on day 0 and day 2. For Th17 transfer passive EAE, CD4+YFPhi
Th17 cells isolated from MOG35–55/CFA-immunized IL-17F
CrexRosa26YFP
fate-mapping mice were adoptively transferred into RAG1/ mice (2.0 3 104
Th17 cells/mouse). To test the suppressive activity of Treg cells, CD4+ICOShi
CCR6+YFPint Tr17 cells or CD4+ICOSloCCR6YFPint resting Treg cells isolated
fromMOG35–55/CFA-immunized Foxp3
YFP-Cre mice were adoptively transferred
into RAG1/ mice together with Th17 cells (8.0 3 104 Treg cells/mouse). The
recipient mice were immunized with MOG35–55/IFA followed by two PTX injec-
tions on the day of immunization and 2 days later. EAE disease progression
was monitored daily, and the disease score was assigned on a scale as follows:
0, no disease; 1, loss of tail tonicity; 2, wobbly gait; 3, hindlimb paralysis; 4, hin-
dlimb and forelimb paralysis; 5, moribund.
Statistical Analysis
Statistical analysis was performed by two-tailed t test. A p value of less than
0.05 was considered statistically significant: *, p < 0.05. **, p < 0.005. All error
bars were drawn based on SE.
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